Lisa Andriani
Shanghai, 200032, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Targeting MORC2 activates transposable element-mediated viral mimicry and potentiates immune checkpoint blockade in triple-negative breast cancer.
Journal: Molecular cancer
Published: November 12, 2025
Enzymatic activity-independent NANS stabilizes LATS2 to drive growth and therapeutic resistance in HR+/HER2- breast cancer.
Journal: Nature communications
Published: June 15, 2025
TBKBP1 induces capecitabine resistance through negative regulation of type I interferon pathway in triple-negative breast cancer.
Journal: Oncogene
Published: March 04, 2025
Bisphosphate nucleotidase 1 promotes progression and docetaxel resistance in triple-negative breast cancer via STUB1-mediated destabilization of LIMA1.
Journal: Cell death & disease
Published: February 28, 2025
Kinesin-like protein KIFC2 stabilizes CDK4 to accelerate growth and confer resistance in HR+/HER2- breast cancer.
Journal: The Journal of clinical investigation
Published: June 04, 2024
Sideroflexin-1 promotes progression and sensitivity to lapatinib in triple-negative breast cancer by inhibiting TOLLIP-mediated autophagic degradation of CIP2A.
Journal: Cancer letters
Published: March 04, 2024
The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer.
Journal: Cancer research
Published: September 14, 2023
ETHE1 Accelerates Triple-Negative Breast Cancer Metastasis by Activating GCN2/eIF2α/ATF4 Signaling.
Journal: International journal of molecular sciences
Published: July 12, 2023
C9orf142 transcriptionally activates MTBP to drive progression and resistance to CDK4/6 inhibitor in triple-negative breast cancer.
Journal: Clinical and translational medicine
Published: May 05, 2023
Destabilization of microrchidia family CW-type zinc finger 2 via the cyclin-dependent kinase 1-chaperone-mediated autophagy pathway promotes mitotic arrest and enhances cancer cellular sensitivity to microtubule-targeting agents.
Journal: Clinical and translational medicine
Published: November 10, 2022
Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer.
Journal: Theranostics
Published: October 09, 2022
Last Updated: 09/26/2026